Modeling and Simulation - PK/PD Archives | 第 25 页，共 38 页

Publication

Modeling of Pharmacokinetic Systems Using Stochastic Deconvolution

In environments where complete mechanistic knowledge of the system dynamics is not available, a synergy…

Certara2013 年 12 月 1 日

Blog Knowledge Base

Understanding Steady State Pharmacokinetics

Certara2013 年 11 月 25 日

Publication

Absence of Pharmacokinetic Drug-drug Interaction of Pertuzumab with Trastuzumab and Docetaxel

Pertuzumab is a novel antihuman epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody. Combined…

Certara2013 年 11 月 24 日

On-Demand Webinar

Phoenix WinNonlin: A State of the Art Software Tool for Pre-clinical PK and TK Analysis

Are you currently using Excel for PK/TK analysis? Phoenix WinNonlin streamlines analyses and generates all…

Certara2013 年 11 月 21 日

知识库

What is Identifiability?

Developing models for pharmacokinetic or pharmacodynamic data requires creativity, patience, and hard work. Sometimes that…

Certara2013 年 11 月 18 日

On-Demand Webinar

Introduction to Population PK/PD Analysis Using Phoenix NLME

Phoenix NLME provides sophisticated algorithms and powerful and flexible data processing and modeling tools for…

Certara2013 年 11 月 14 日

Publication

Predicted Heart Rate Effect of Inhaled LABA PF-00610355 in Volunteers and COPD Patients

The aim of this study was to assess the cardiovascular effects of a new inhaled…

Certara2013 年 11 月 1 日

知识库

What is the -2LL or the Log-likelihood Ratio?

Understand the 2LL (Log-likelihood Ratio) and its role in statistical analysis. Explore how it aids…

Certara2013 年 10 月 28 日

Publication

Prediction of Overall Survival or Progression Free Survival by Disease Control Rate at Week 8 Is Independent of Ethnicity: Western Versus Chinese Patients with First-line Non-small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab

Categorizations of best response observed at week 8 of first-line treatment in two studies of…

Certara2013 年 10 月 22 日

Knowledge Base

Using Sampling “Windows” for PK Blood Samples

One of the most common questions posed by clinical operations experts when including pharmacokinetic sampling…

Certara2013 年 10 月 15 日

Modeling and Simulation – PK/PD

Modeling of Pharmacokinetic Systems Using Stochastic Deconvolution

Understanding Steady State Pharmacokinetics

Absence of Pharmacokinetic Drug-drug Interaction of Pertuzumab with Trastuzumab and Docetaxel

Phoenix WinNonlin: A State of the Art Software Tool for Pre-clinical PK and TK Analysis

What is Identifiability?

Introduction to Population PK/PD Analysis Using Phoenix NLME

Predicted Heart Rate Effect of Inhaled LABA PF-00610355 in Volunteers and COPD Patients

What is the -2LL or the Log-likelihood Ratio?

Prediction of Overall Survival or Progression Free Survival by Disease Control Rate at Week 8 Is Independent of Ethnicity: Western Versus Chinese Patients with First-line Non-small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab

Using Sampling “Windows” for PK Blood Samples

订阅时事通讯

快捷链接

解决方案

联系我们